ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients

Liu, Zhihong; Jin, Qinglong; Zhang, Yuexin; Gong, Guozhong; Wu, Guicheng; Yao, Lvfeng; Wen, Xiaofeng; Gao, Zhiliang; Huang, Yan; Yang, Daokun; Chen, Enqiang; Mao, Qing; Lin, Shide; Shang, Jia; Gong, Huanyu; Zhong, Lihua; Yin, Huafa; Wang, Fengmei; Hu, Peng; Wu, Qiong; Pan, Chao; Jia, Wen; Li, Chuan; Sun, Chang'a; Niu, Junqi*; Hou, Jinlin*安徽医科大学; 吉林大学; 南方医科大学; 哈尔滨医科大学; 四川大学; 中山大学; 重庆大学; 1
Journal of Clinical and Translational Hepatology2023-6DOI: 10.14218/JCTH.2022.00058
3被引3阅读
引用收藏
分享

摘要

Background and Aims: Tenofovir amibufenamide (TMF) is a novel phosphoramidated prodrug of tenofovir with noninferior efficacy and better bone and renal safety to tenofovir disoproxil fumarate (TDF) in 48 weeks of treatment. Here, we update 96-week comparison results. Methods: Patients with chronic hepatitis B were assigned (2:1) to receive either 25 mg TMF or 300 mg TDF with matching placebo for 96 weeks. The virological suppression was defined as HBV DNA levels <20 IU/mL at week 96. Safety was evaluated thoroughly with focusing on bone, renal, and metabolic parameters. Results: Virological suppression rates at week 96 were similar between TMF and TDF group in both HBeAg-positive and HBeAg-negative populations. Noninferior efficacy was maintained in the pooled population, while it was first achieved in patients with HBV DNA =7 or 8 log10 IU/mL at baseline. Non-indexed estimated glomerular filtration rate for renal safety assessment was adopted, while a smaller decline of which was seen in the TMF group than in the TDF group (p=0.01). For bone mineral density, patients receiving TMF displayed significantly lower reduction levels in the densities of spine, hip, and femur neck at week 96 than those receiving TDF. In addition, the lipid parameters were stable after week 48 in all groups while weight change still showed the opposite trend. Conclusions: TMF maintained similar efficacy at week 96 compared with TDF with continued superior bone and renal safety profiles (NCT03903796).

学科与关键词

关键词
Hepatitis BLiver function testsViral hepatitisLiverOsteoporosis
相关
加载中…
  • Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B
    Liu, Zhihong; Jin, Qinglong; Zhang, Yuexin; Gong, Guozhong; Wu, Guicheng; Yao, Lvfeng; Wen, Xiaofeng; Gao, Zhiliang; Huang, Yan; Yang, Daokun; Chen, Enqiang; Mao, Qing; Lin, Shide; Shang, Jia; Gong, Huanyu; Zhong, Lihua; Yin, Huafa; Wang, Fengmei; Hu, Peng; Xiao, Ling; Li, Chuan; Wu, Qiong; Sun, Chang'an; Niu, Junqi*; Hou, Jinlin*Alimentary Pharmacology and Therapeutics, 2021, 54(9): 1134-1149.被引 9
  • 3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China
    Hou, Jinlin*; Ning, Qin*; Duan, Zhongping; Chen, You; Xie, Qing; Wang, Fu-Sheng; Zhang, Lunli; Wu, Shanming; Tang, Hong; Li, Jun; Lin, Feng; Yang, Yongfeng; Gong, Guozhong; Flaherty, John F.; Gaggar, Anuj; Mo, Shuyuan; Cheng, Cong; Camus, Gregory; Chen, Chengwei; Huang, Yan; Jia, Jidong; Zhang, MingxiangJournal of Clinical and Translational Hepatology, 2021, 9(3): 324-334.被引 17
  • Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?
    Liang, Xieer; Xie, Qing; Shang, Jia; Tang, Hong; Xu, Min; Meng, Qinghua; Zhang, Jiming; Gao, Pujun; Sheng, Jifang; Wang, Hao; Jia, Jidong; Wang, Guiqiang; Wu, Shunquan; Ping, Jingna; Hou, Jinlin*Journal of Gastroenterology and Hepatology, 2022, 37(3): 471-479.
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Clinical and Translational Hepatology
发表日期
2023-06
卷期
第 11 卷, 第 3 期
页码
649-660
DOI
10.14218/JCTH.2022.00058
成果收录
SCIE
资助标注
Hansoh Pharmaceuticals Co., Ltd.

作者

  • L

    Liu, Zhihong (第一作者)

    southern med univ

  • J

    Jin, Qinglong

    jilin univ

查看全部 26 位作者收起作者
  • Z

    Zhang, Yuexin

  • G

    Gong, Guozhong

    2

  • W

    Wu, Guicheng

    chongqing univ

  • Y

    Yao, Lvfeng

    fujian med univ

  • W

    Wen, Xiaofeng

    liuzhou peoples hosp

  • G

    Gao, Zhiliang

    zhongshan univ

  • H

    Huang, Yan

  • Y

    Yang, Daokun

    1 · xinxiang med univ

  • C

    Chen, Enqiang

    sichuan univ

  • M

    Mao, Qing

  • L

    Lin, Shide

  • S

    Shang, Jia

    henan prov peoples hosp

  • G

    Gong, Huanyu

  • Z

    Zhong, Lihua

    harbin med univ

  • Y

    Yin, Huafa

    1 · anhui med univ

  • W

    Wang, Fengmei

    tianjin third cent hosp

  • H

    Hu, Peng

    2 · chongqing med univ

  • W

    Wu, Qiong

  • P

    Pan, Chao

  • J

    Jia, Wen

  • L

    Li, Chuan

  • S

    Sun, Chang'a

  • N

    Niu, Junqi (通讯)

    jilin univ

  • H

    Hou, Jinlin (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417